Hostname: page-component-77c89778f8-vsgnj Total loading time: 0 Render date: 2024-07-18T22:24:59.889Z Has data issue: false hasContentIssue false
  • English
  • Français

FC03-04 - Lamotrigine treatment of acute alcohol hallucinosis comorbid depersonalizations disorders: A randomimized double-blind, placebo-controlled study

Published online by Cambridge University Press:  16 April 2020

N. Aliyev ,
A.A. Aliyev ,
Z.N. Aliyev  and
A. Aliyev
N. Aliyev
Affiliation:
Central Mental Clinic for Outpatients of Baku City, Baku, Azerbaijan
A.A. Aliyev
Affiliation:
Central Mental Clinic for Outpatients of Baku City, Baku, Azerbaijan
Z.N. Aliyev
Affiliation:
Psychiatric Department of Azerbaijan State Medical University, Baku, Azerbaijan
A. Aliyev
Affiliation:
Central Mental Clinic for Outpatients of Baku City, Baku, Azerbaijan

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims

We compared the efficacy and safety of lamotrigine versus placebo for the treatment of acute alcohol hallucinosis comorbid depersonalization disorders.

Methods

10 days, randomized, double-blind, parallel study. A total of 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis comorbid depersonalization disorders were randomized to lamotrigine 300 mg/d (n = 40), or placebo (n = 40). The primary efficacy measure was the PANSS subscale for hallucinosis and Cambridge Depersonalization Scale (CDS).

Results

Iamotrigine treated patients demonstrated a statistically significant greater improvement in PANSS subscale for hallucinosis and CDS than placebo-treated patients.

Conclusion

Lamotrigine demonstrated greater efficacy than placebo in treatment of acute hallucinosis comorbid depersonalization disorders and was generally well tolerated.

Type
Research Article
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1825
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.